A large review combined data from multiple studies involving 3,720 people diagnosed with polycystic ovary syndrome (PCOS). The goal was to determine if measuring LAP levels could accurately identify which of these patients also have metabolic syndrome, a cluster of conditions that increase the risk of heart disease and diabetes.
The analysis showed that LAP levels were significantly elevated in PCOS patients who had metabolic syndrome compared to those without it. The pooled mean difference was 2.52 units, indicating a clear distinction between the two groups. The study also calculated sensitivity, specificity, and the area under the curve to assess how well LAP performs as a screening tool.
No safety concerns were reported because LAP is a blood marker, not a medication. Readers should understand that while LAP levels appear linked to metabolic syndrome in this group, this is a diagnostic accuracy study. It does not prove that LAP causes the condition. Further research is needed to confirm if LAP should be used alongside other tests in everyday medical practice.